# EDGAR Filing Document

**Accession Number:** 0001985062
**File Stem:** 0001539497-25-003250
**Filing Date:** 2025-12
**Character Count:** 16351
**Document Hash:** 1c12c05769806dfc2ed4fdcc1d2d8a13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001539497-25-003250.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001539497-25-003250

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PSYENCE BIOMEDICAL LTD.
- **CENTRAL INDEX KEY:** 0001985062
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94325
- **FILM NUMBER:** 251562990

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **BUSINESS PHONE:** 27744604171

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kaos Capital Ltd
- **CENTRAL INDEX KEY:** 0002100448

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 118 YORKVILLE AVENUE
- **STREET 2:** SUITE 604
- **CITY:** TORONTO
- **NON US STATE TERRITORY:** ONTARIO, CANADA
- **PROVINCE COUNTRY:** A6
- **ZIP:** M5R 1C2
- **BUSINESS PHONE:** 416 930 1221

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 118 YORKVILLE AVENUE
- **STREET 2:** SUITE 604
- **CITY:** TORONTO
- **NON US STATE TERRITORY:** ONTARIO, CANADA
- **PROVINCE COUNTRY:** A6
- **ZIP:** M5R 1C2

## Exhibit 99.1

**Exhibit 99.1**

**<u>Schedule 1</u>**

**CONTROL PERSONS AND EXECUTIVE OFFICERS OF REPORTING PERSONS**

The name, business address, present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted, of each of the executive officers and other control persons of the Reporting Persons are set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **Name and Business Address** | **Capacity in which**<br> **Serves KAOS** | **Principal Occupation** | **Name, Principal Business and**<br> **Address of Organization in**<br> **which Principal Occupation**<br> **is Conducted** |
| Adam Arviv<br> KAOS Capital Ltd.<br> 118 Yorkville Avenue, Suite 604<br> Toronto, Ontario, Canada M5R 1C2<br> Email: aa@kaos.capital | Founder, Chief Executive Officer and Sole Director | Founder, Chief Executive Officer and Sole Director of Kaos | KAOS Capital Ltd.<br> 118 Yorkville Avenue, Suite 604<br> Toronto, Ontario, Canada M5R 1C2 |

---

## Exhibit 99.2

**Exhibit 99.2**

**<u>Schedule 2</u>**

**TRANSACTIONS**

The Reporting Persons have entered into a number of transactions in the shares of Common Stock within the past sixty (60) days. All purchases have been made by KAOS on the open market through its broker at the then applicable open market trading price per share. A complete list of such transactions is set forth below:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Date** | **Reporting Person** | **How Transaction Effected** | **Price Per Share** | **Number of Shares** | **Total** |
| 11/24/2025 | KAOS Capital Ltd. | Open market purchase | $1.69795 | 25000 | $42448.75 |
| 11/26/2025 | KAOS Capital Ltd. | Open market purchase | $1.51205 | 75000 | $113403.75 |
| 12/01/2025 | KAOS Capital Ltd. | Open market purchase | $1.57620 | 20000 | $31524.00 |
| 12/01/2025 | KAOS Capital Ltd. | Open market purchase | $1.61309 | 3212 | $5181.25 |
| 12/01/2025 | KAOS Capital Ltd. | Open market purchase | $1.59370 | 10664 | $16995.22 |
| 12/01/2025 | KAOS Capital Ltd. | Open market purchase | $1.56807 | 20000 | $31361.40 |
| 12/01/2025 | KAOS Capital Ltd. | Open market purchase | $1.53346 | 20000 | $30669.20 |
| 12/03/2025 | KAOS Capital Ltd. | Open market purchase | $1.74765 | 48961 | $85566.69 |
| 12/04/2025 | KAOS Capital Ltd. | Open market purchase | $1.80385 | 51039 | $92066.70 |
| 12/08/2025 | KAOS Capital Ltd. | Open market purchase | $1.75691 | 40000 | $70276.40 |
|  |  |  | **Total** | **313876** | **$519493.36** |

---

## Exhibit 99.3

**Exhibit 99.3**

**JOINT FILING AGREEMENT**

**PURSUANT TO RULE 13d-1(k)**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: December 10, 2025

---

| | |
|:---|:---|
|  | KAOS Capital Ltd. |
| By: | /s/ Adam Arviv |
|  | Name: Adam Arviv |
|  | Title: Chief Executive Officer |

---

---

| | |
|:---|:---|
|  | Adam Arviv |
| By: | /s/ Adam Arviv |
|  | Name: Adam Arviv |
|  | Title: Adam Arviv, Individually |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**PSYENCE BIOMEDICAL LTD.**

*(Name of Issuer)*

**Common Stock, without par value**

*(Title of Class of Securities)*

**74449F308**

*(CUSIP Number)*

**Adam Arviv**<br>KAOS Capital Ltd.<br>118 Yorkville Avenue, Suite 604<br>Toronto, Ontario A6 M5R 1C2<br>(416) 930-1221

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/25/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74449F308** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**KAOS Capital Ltd.** | Name of reporting person<br>**KAOS Capital Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ONTARIO** | Citizenship or place of organization<br>**ONTARIO** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**313876.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**313876.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**313876.00** | Aggregate amount beneficially owned by each reporting person<br>**313876.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**16.77%** | Percent of class represented by amount in Row (11)<br>**16.77%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** *Based on 1,872,051 shares of Common Stock outstanding on September 30, 2025, as reported in the Issuer's Unaudited Condensed Consolidated Financial Statements for the three and six months ended September 30, 2025 and 2024 as attached to Form 6-K filed with the Securities and Exchange Commission on November 20, 2025.

| **CUSIP No.** | **74449F308** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Adam Arviv** | Name of reporting person<br>**Adam Arviv** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ONTARIO** | Citizenship or place of organization<br>**ONTARIO** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**313876.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**313876.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**313876.00** | Aggregate amount beneficially owned by each reporting person<br>**313876.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**16.77%** | Percent of class represented by amount in Row (11)<br>**16.77%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** *Based on 1,872,051 shares of Common Stock outstanding on September 30, 2025, as reported in the Issuer's Unaudited Condensed Consolidated Financial Statements for the three and six months ended September 30, 2025 and 2024 as attached to Form 6-K filed with the Securities and Exchange Commission on November 20, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, without par value

**(b) Name of Issuer:**
PSYENCE BIOMEDICAL LTD.

**(c) Address of Issuer's Principal Executive Offices:**
121 RICHMOND STREET WEST PENTHOUSE, SUITE 1300, TORONTO, Ontario, A6, M5H 2K1

This statement on Schedule 13D (this "Schedule 13D") relates to the common stock, without par value (the  "Common Stock"), of Psyence Biomedical Ltd., an Ontario corporation (the "Issuer"). The Reporting Persons are  first time Edgar filers who did not previously have Edgar filing codes. While every effort was made to timely file  this Schedule 13D, the filing was ultimately delayed due to the time required to process a new Form ID and obtain  Edgar filing codes.

**Item 4. Purpose of Transaction**

The Reporting Persons believe the securities of the Issuer are undervalued and represent an attractive investment opportunity. The Reporting Persons intend to communicate with the Issuer's management and Board about a broad range of operational, management, corporate and strategic matters, and may communicate with other stockholders or third parties about such matters.

The Reporting Persons intend to review their investment in the Issuer on a continuing basis, and depending upon various factors, including without limitation, the Issuer's financial position and strategic direction, the outcome of any discussions referenced above, overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor (i) to increase or decrease their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer, including through transactions involving the shares Common Stock and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Issuer in the open market or in private transactions, on such terms and at such times as the Reporting Persons may deem advisable and/or (ii) to enter into transactions that increase or decrease their economic exposure to the shares of Common Stock without affecting their beneficial ownership of the shares of Common Stock or adjust their exposure to the shares of Common Stock in ways that would affect their beneficial ownership of the shares of Common Stock.

Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each of the Reporting Persons.

**(b)**
See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

**(c)**
The Reporting Persons have entered into a number of transactions in the shares of Common Stock within the past sixty (60) days. All purchases have been made by KAOS on the open market through its broker at the then applicable open market trading price per share. A complete list of such transactions is set forth on Schedule 2 attached hereto as Exhibit 99.2.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Mr. Arviv is the founder and chief executive officer of KAOS. In such role, he manages all the business, affairs and investments of KAOS, which would include the ownership of the Common Stock.

Other than as disclosed herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer, including any class of the Issuer's securities used as a reference security, in connection with any of the following: call options, put options, security-based swaps or any other derivative securities, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** KAOS Capital Ltd.

**Signature:** /s/ Adam Arviv

**Name/Title:** Adam Arviv / Chief Executive Officer

**Date:** 12/10/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Adam Arviv

**Signature:** /s/ Adam Arviv

**Name/Title:** Adam Arviv, Individually

**Date:** 12/10/2025